Alnylam Pharmaceuticals' Other Working Capital Changes fell 300.64% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year increase of 67.92%. This contributed to the annual value of -$235.4 million for FY2024, which is 527.91% down from last year.
Alnylam Pharmaceuticals' Other Working Capital Changes amounted to -$12.5 million in Q3 2025, which was up 82.86% from -$73.2 million recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Other Working Capital Changes ranged from a high of $75.5 million in Q1 2024 and a low of -$295.0 million during Q2 2024.
In the last 3 years, Alnylam Pharmaceuticals' Other Working Capital Changes had a median value of -$3.1 million in 2024 and averaged -$21.2 million.
As far as peak fluctuations go, Alnylam Pharmaceuticals' Other Working Capital Changes tumbled by 1,267.23% in 2022, and later skyrocketed by 688.31% in 2024.
Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Other Working Capital Changes stood at $9.7 million in 2021, then crashed by 1,267.23% to -$113.1 million in 2022, then soared by 115.64% to $17.7 million in 2023, then slumped by 172.42% to -$12.8 million in 2024, then tumbled by 300.64% to -$12.5 million in 2025.
Its last three reported values are -$12.5 million in Q3 2025, -$73.2 million for Q2 2025, and $32.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value